G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement 11 March 2020

GENERATION 3 – 'GLUCOSE' PRIZMA

- **Blood Glucose module successfully integrated into Prizma medical device**
- **G Medical's Prizma 'G3' adds chemical tests to the medical device**
- **G Medical positioning its technology offerings towards the growing Blood Glucose monitoring market**
- **Expanding Prizma's chronic condition monitoring abilities including diabetes, neuropathy, retinopathy, cardiovascular diseases**

Mobile and e-Health company **G Medical Innovations Holdings Limited (ASX:GMV) ("G Medical" "the Company")**, is pleased to advise its shareholders it has successfully integrated the blood glucose module into the innovative Prizma medical device.

As previously advised, the Company has continued its research and development efforts towards its future generation of Prizma device which will provide the additional technology offering of an array of chemical and laboratory type tests and diagnostic capabilities. Blood tests and chemical pathology are used routinely in health care to determine physiology and biochemical states, being an important modality in disease diagnosis, progression and monitoring, mineral content analysis, pharmaceutical drug effectiveness and organ function.

Known as the Prizma Generation 3 ("G3"), with the view to becoming a mobile laboratory, these additional feature sets will become an appealing diagnostic and management tool for both patients and individuals with specific chronic illness management, as well as for those wanting convenient and reliable access to a more general and broader spectrum of personal physiological chemistry and biochemistry data and analysis.

The mobility and portability of the Prizma G3, makes for an appealing medical device for remote patient monitoring and 'out of clinic' care and diagnosis; as well as being a tool for physicians and practitioners to utilise as an in-clinic laboratory for convenient and immediate analysis for certain medical indications and pathology needs.

The procuring of blood tests and other laboratory based tests generally requires the patient or individual to seek consultation with their physician or practitioner, obtain the prescription for the test/s, attend the pathology clinic for the sample/s, and wait for the laboratory analysis. These typical processes are both time consuming and generally inconvenient to the patient and burdensome for the health care system. With this in mind, patient compliance may be challenging or compromised, particular for those that require regular analysis and monitoring for their specific medical indication or their treatment needs.

Additionally, the Prizma G3's chemical tests are automatically synced and stored into the Prizma's existing mobile platform and recorded on the individual's personal electronic medical record ("EMR"). As with the current Prizma's EMR functionality, the Prizma G3's EMR can also be shared digitally and instantaneously with the patient's physician, health care provider and/or guardian on election, as well as provide in-APP guidance on the analysis.

Image one: Proposed design for G Medical's Prizma G3

Prizma G3 - Blood Glucose Test

The Blood Glucose Test is the first test integration to the Prizma G3, with another 5 chemical tests currently in further development. The blood glucose test is a simple, accurate and reliable test designed for advanced diabetes management. The Prizma G3 Blood Glucose Test requires a very small sample size (0.5 µL of blood) and a 5-second reaction time, with the results assisting the user to make timely lifestyle changes towards avoiding hypoglycemia or hyperglycemia.

Specifications of the Prizma G3 Blood Glucose Module and Test Strip

BGM Module	
Operating Altitude	Up to 3,045 Meters
Operating Temperature	+8ºC ~ +45ºC
Operating Humidity	10% ~ 90%
Storage Temperature	-20ºC ~ +60ºC
Storage Humidity	Less than 90%
Electrical	Prizma Power Source
Blood Glucose Test Strip	
Strip Performance	Enzyme Type
Sample Size	0.5 uL
Reaction Time	Up to 5 Seconds
Blood Detect	With Blood Detect
Alternative Site Testing	With AST
Coding Type	No Code
Sample Type	Whole Blood Capillary or Venous
Accuracy / Precision	ISO 15197:2013
Measuring Range (BG)	10mg/dL ~ 600mg/dL
Operating Altitude	Up to 3,045 Meters

Operating Temperature	+8ºC ~ +45ºC
Operating Humidity	Less than 85%
Storage Temperature	+2ºC ~ +30ºC
Storage Humidity	Less than 85%
Shelf Life	24 / 21 Months (Vial)
Dimension	30.0 x 7.5 x 0.45 (mm)

G Medical will conduct external (3rd party) clinical studies as required by regulators within the territory it decides to enter. The Company looks forward to updating shareholder on the progress of the Prizma G3.

Management commentary:

CEO and Executive Director Dr Yacov Geva said: "The integration of a Blood Glucose module will significantly strengthen G Medical's Prizma product and is a major development in the Company creating a portable laboratory for patients. It also leaves the Company well positioned in the current climate, as patients move towards remote patient monitoring and 'out of clinic' care.

"The addition of a blood glucose test provides will pave the way for an additional five chemistry tests under development. Third party clinical studies required by regulatory bodies will commence as soon as possible and the Company looks forward to updating shareholders as they progress."

Background on the Blood Glucose Monitoring Market[1,2]

The global blood glucose monitoring market is expected to register a CAGR of 11.88% during the forecast period of 2019 - 2024; the market is estimated to reach USD 12.8 billion by 2019. Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. Key factors driving this market are rising incidence of diabetes, coupled with increasing geriatric population prone to diabetes.

The market is further propelled by growing awareness about diabetes preventive care, new product launches, and supportive government initiatives. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices. Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes. According to the International Diabetes Federation, approximately 424 million people were living with diabetes in 2017 and this number is expected to reach 629 million by 2045.

Blood glucose monitoring devices are economically beneficial and vital for proper diagnosis and treatment. These devices are used to measure blood sugar levels and is an essential step in diabetes treatment. They also help in preventing other related health conditions such as neuropathy, retinopathy, and cardiovascular diseases.

Other market driving factors include technological innovations and advancements, which provide for much convenience in measuring the blood glucose levels. These devices help in the early detection of hypo and hyperglycemic conditions, which tend to drive the market for glucose monitoring. Self-monitoring blood glucose devices (SMBG) are the most preferred device by the patients due to its economic affordability and less sophisticated usage, with SMBG devices occupying more than 87% of the share in the blood glucose monitoring market. In 2018, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, which showed moderate growth. Asia-Pacific, Latin America, and the Middle East & Africa showed low growth due to economic affordability. Low cost, connectable and accessible devices are a key benefit in emerging market adoption.

The home care segment is expected to register the fastest CAGR of 7.7% during the forecast period. Home-based glucose monitoring has been revolutionized by self-monitoring solutions and devices and is the most widely used method of short-term glucose monitoring globally. People with or without diabetes can measure their blood sugar levels with ease and convenience in their homes. Based on the reading, patients can check the effects of their treatment such as diet, insulin, exercise, and stress management.



Image two: North American blood glucose monitoring devices market size, by product, 2015 – 2026 (USD billion)

Authorised for release by Dr Yacov Geva, CEO and Managing Director of the Company.

-Ends-

Investor Relations:
Henry Jordan
Six Degrees
+61 (0) 431 271 538

About G Medical Innovations

G Medical **(ASX: GMV)** was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

References:

1. Blood glucose monitoring market - growth, trends and forecast (2012 - 2024); Industry Research Co. SKU ID: INH 14245-404, 1 February 2019.
2. Blood Glucose Monitoring Devices Market Size, Share & Trends Analysis Report By End Use (Hospital, Homecare, Diagnostic Centers), By Product (Self & Continuous Monitoring), And Segment Forecasts, 2019 – 2026; Grand View Research: Report ID: GVR-3-68038-688-2; September.